Skip to main content
. 2020 Jan 21;130(2):942–957. doi: 10.1172/JCI127425

Figure 10. Siro activates Smad1/5/8 via ALK2.

Figure 10

(AD) HUVECs (AC) and HHT2 patient–derived BOECs (D) were treated for 3 hours with vehicle (DMSO) or Siro in complete medium (conditioned for 2–3 days) and at the indicated concentrations (A and D) or at 300 nM (B and C), in the absence or presence of LDN-193189 (LDN, 1 μM, B), or the indicated siRNA treatments (C). Cell extracts were analyzed by Western blot using antibodies directed against the indicated proteins.